Zobrazeno 91 - 100
of 1 457
pro vyhledávání: ''
Autor:
Mariano Provencio, Jonathon B. Cohen, Eva Domingo-Domenech, Azra H. Ligon, Jing Ouyang, Margaret A. Shipp, Hun Ju Lee, Marek Trněný, Tatyana Feldman, Wolfgang Willenbacher, Mariana Sacchi, Radhakrishnan Ramchandren, Kerry J. Savage, Anne Sumbul, Philippe Armand, Robert A. Redd, Antonio Rueda, Christian Sillaber, Scott J. Rodig, Stephen M. Ansell
Publikováno v:
Journal of Clinical Oncology. 37:1997-2007
PURPOSE Nivolumab, an anti–programmed death-1 monoclonal antibody, has demonstrated frequent and durable responses in relapsed/refractory classic Hodgkin lymphoma (cHL). We report results from Cohort D of the CheckMate 205 trial, which assessed niv
Autor:
Anika E. Adeni, Mizuki Nishino, Suzanne E. Dahlberg, Lynette M. Sholl, Biagio Ricciuti, Mark M. Awad
Publikováno v:
Journal of Clinical Oncology. 37:1927-1934
PURPOSE Baseline use of corticosteroids is associated with poor outcomes in patients with non–small-cell lung cancer (NSCLC) treated with programmed cell death-1 axis inhibition. To approach the question of causation versus correlation for this ass
Autor:
Nick M. Spirtos, James J. Burke, David Miller, Jae Weon Kim, Marcus E. Randall, Paul DiSilvestro, Robert S. Mannel, Virginia L. Filiaci, Penny R. Anderson, William Small, Ritu Salani, Keith Terada, Helen J. Huang, Wendy R. Brewster, Vivian E. von Gruenigen, Carol Aghajanian, Catheryn M. Yashar, D. Scott McMeekin, Thomas J. Rutherford
Publikováno v:
Journal of Clinical Oncology. 37:1810-1818
PURPOSE The primary objective was to determine if vaginal cuff brachytherapy and chemotherapy (VCB/C) increases recurrence-free survival (RFS) compared with pelvic radiation therapy (RT) in high-intermediate and high-risk early-stage endometrial carc
Autor:
Jeremy S. Abramson, Heiko Schöder, Wyndham H. Wilson, Richard I. Fisher, Nancy L. Bartlett, Matthew J. Maurer, Levi Pederson, John P. Leonard, Jane N. Winter, Nishitha Reddy, Louis M. Staudt, Nina D. Wagner-Johnston, Kristie A. Blum, Susan Mathew, Julie E. Chang, Ajay K. Gopal, Jonathan W. Friedberg, Brad S. Kahl, Amy Chadburn, Kristy L. Richards, Brandelyn N. Pitcher, Bruce D. Cheson, Mei Yin C. Polley, Andrew D. Zelenetz, Eric D. Hsi, Sin-Ho Jung
Publikováno v:
Journal of Clinical Oncology. 37:1790-1799
PURPOSE Alliance/CALGB 50303 (NCT00118209), an intergroup, phase III study, compared dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) with standard rituximab, cyclophosphamide, doxorubicin, v
Autor:
Siddhartha Mitra, Bruce D. Cheson, Julie Huang, Michael Hallek, Susan O'Brien, Jacqueline C. Barrientos, Stephan Stilgenbauer, Bertrand Coiffier, Shuo Ma, John M. Pagel, Herbert Eradat, Andrew D. Zelenetz, Steven Coutre, Andrew R. Pettitt, Nicole Lamanna, Richard R. Furman, Thomas J. Ervin, Jeff P. Sharman, Thomas J. Kipps, Paula Cramer, Paolo Ghia, Eugen Tausch, Ian W. Flinn, Peter Hillmen
Publikováno v:
Journal of Clinical Oncology
PURPOSE A randomized, double-blind, phase III study of idelalisib (IDELA) plus rituximab versus placebo plus rituximab in patients with relapsed chronic lymphocytic leukemia (CLL) was terminated early because of superior efficacy of the IDELA-plus-ri
Autor:
Philip Silberman, Alexander P. Glaser, Anuj S. Desai, Jason Cohen, Brian J. Jordan, Joshua J. Meeks
Publikováno v:
JCO Precision Oncology. :1-6
Purpose Bladder cancer is initially diagnosed and staged with a transurethral resection of bladder tumor (TURBT). Patient survival is dependent on appropriate sampling of layers of the bladder, but pathology reports are dictated as free text, making
Autor:
Angela B. Mariotto, Ann S. Hamilton, Lynne Penberthy, Steven J. Katz, Dennis Deapen, Kevin C. Ward, Nadia Howlader, Daniel H. Miller, Allison W. Kurian
Publikováno v:
J Clin Oncol
PURPOSE Genetic testing for cancer risk has expanded rapidly. We examined clinical genetic testing and results among population-based patients with breast and ovarian cancer. METHODS The study included all women 20 years of age or older diagnosed wit
Autor:
Sirpa Leppä, Su-Peng Yeh, Ronit Gurion, Mehmet Turgut, Sriram Balasubramanian, Laurie H. Sehn, Anas Younes, Sen Hong Zhuang, Xiaonan Hong, Pier Luigi Zinzani, Andres Lopez-Hernandez, Shinya Rai, Caterina Patti, S. Martin Shreeve, Wojciech Jurczak, David Belada, Matthew C. Cheung, Olga Samoilova, Cheolwon Suh, Jessica Vermeulen, Louis M. Staudt, Jodi Carey, Catherine Thieblemont, Peter Johnson, C.S. Chiattone, Ulrich Dührsen, Grace Liu, Wyndham H. Wilson, Steven Sun, Jun Zhu
Publikováno v:
Journal of Clinical Oncology. 37:1285-1295
60th Annual Meeting of the American-Society-of-Hematology (ASH) -- DEC 01-04, 2018 -- San Diego, CA Jurczak, Wojciech/0000-0003-1879-8084; Johnson, Peter/0000-0003-2306-4974; ZINZANI, PIER LUIGI/0000-0002-2112-2651; Leppa, Sirpa/0000-0002-8265-511X W
Autor:
Leonard, John P, Trneny, Marek, Izutsu, Koji, Fowler, Nathan H, Hong, Xiaonan, Zhu, Jun, Zhang, Huilai, Offner, Fritz, Scheliga, Adriana, Nowakowski, Grzegorz S, Pinto, Antonio, Re, Francesca, Fogliatto, Laura Maria, Scheinberg, Phillip, Flinn, Ian W, Moreira, Claudia, Cabecadas, Jose, Liu, David, Kalambakas, Stacey, Fustier, Pierre, Wu, Chengqing, Gribben, John G, Calaminici, Maria, Copie-Bergman, Christiane, Lopez-Guillermo, Armando, O'Connor, Owen, Williams, Michael, Suciu, Stefan, Levine, Benjamin, Kern, Julie
Publikováno v:
Journal of Clinical Oncology
JOURNAL OF CLINICAL ONCOLOGY
JOURNAL OF CLINICAL ONCOLOGY
PURPOSE Patients with indolent non-Hodgkin lymphoma typically respond well to first-line immunochemotherapy. At relapse, single-agent rituximab is commonly administered. Data suggest the immunomodulatory agent lenalidomide could increase the activity
Autor:
Alan P. Venook, Monica M. Bertagnolli, Hanna K. Sanoff, Xueping Qu, Shilpi Mahajan, Tyler Zemla, Blase N. Polite, Federico Innocenti, Donna Niedzwiecki, James M Atkins, Omar Kabbarah, Heinz-Josef Lenz, Fang-Shu Ou, Charles D. Blanke, Rachel Tam, Richard M. Goldberg
Publikováno v:
Journal of Clinical Oncology. 37:1217-1227
PURPOSE CALGB/SWOG 80405 was a randomized phase III trial that found no statistically significant difference in overall survival (OS) in patients with first-line metastatic colorectal cancer treated with chemotherapy plus either bevacizumab or cetuxi